Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR

Journal of Psychopharmacology
K HewettJ Modell

Abstract

Bupropion, a noradrenaline/dopamine reuptake inhibitor, and venlafaxine, a serotonin/noradrenaline reuptake inhibitor, are both established antidepressants with proven efficacy in randomized controlled clinical trials. The objective of this double-blind, randomized, placebo- and active-controlled, eight-week, flexible-dose study was to evaluate the efficacy and tolerability of the once-daily extended-release formulations of these two antidepressants compared with placebo. Patients with major depressive disorder were randomized to once-daily treatment with bupropion XR 150 mg (n = 204), the extended-release formulation of venlafaxine (venlafaxine XR) 75 mg (n = 198) or placebo (n = 189) during weeks 1 to 4, with the option to double the dose at week 5 if response was inadequate. In this study, bupropion XR did not demonstrate statistically significant evidence of greater improvement from baseline compared with placebo on week 8 Montgomery Asberg Depression Rating scale scores (primary endpoint) or on secondary endpoints including CGI, HAM-A and responder and remitter analyses. Descriptive statistics for venlafaxine XR indicated separation versus placebo on MADRS total scores at week 8 and other intermediate time points, and on o...Continue Reading

References

Jun 1, 1996·Journal of Clinical Psychopharmacology·R L Rudolph, A T Derivan
Feb 4, 1998·The Journal of Clinical Psychiatry·R J KavoussiJ A Johnston
Jan 5, 2000·The American Journal of Psychiatry·D A Lewis
May 19, 2000·The Journal of Clinical Psychiatry·K L WeihsJ A Ascher
Dec 1, 2000·Depression and Anxiety·J P Staab, D L Evans
Dec 19, 2002·American Journal of Physiology. Gastrointestinal and Liver Physiology·Heather J ChialDebra Stephens
Mar 14, 2003·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Dan G Blazer
Sep 14, 2004·Primary Care Companion to the Journal of Clinical Psychiatry·Stephen M. StahlSusan Learned-Coughlin
Jul 20, 2005·Primary Care Companion to the Journal of Clinical Psychiatry·Maurizio FavaJ Andrew Johnston
Mar 24, 2006·The New England Journal of Medicine·A John RushUNKNOWN STAR*D Study Team
Sep 16, 2006·Journal of Clinical Psychopharmacology·Michael E ThaseJ Andrew Johnston

❮ Previous
Next ❯

Citations

Dec 16, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Juan Undurraga, Ross J Baldessarini
Dec 16, 2010·CNS Neuroscience & Therapeutics·Bernardo Dell'OssoA Carlo Altamura
May 21, 2011·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alessandro SerrettiDiana De Ronchi
May 4, 2016·Therapeutic Advances in Psychopharmacology·Krisna PatelDerek K Tracy
Nov 23, 2010·Current Opinion in Psychiatry·Salvatore Gentile
Sep 8, 2017·Depression and Anxiety·Chad BeyerMichael H Bloch
Jul 28, 2016·International Clinical Psychopharmacology·Michael E ThaseAngelo Sambunaris

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.